The DOI matches its Crossref record.
Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects
Open accessAbstract
Matrix metalloproteinase-13 (MMP13) is a Zn(2+)-dependent protease that catalyzes the cleavage of type II collagen, the main structural protein in articular cartilage. Excess MMP13 activity causes cartilage degradation in osteoarthritis, making this protease an attractive therapeutic target. However, clinically tested MMP inhibitors have been associated with a painful, joint-stiffening musculoskeletal side effect that may be due to their lack of selectivity. In our efforts to develop a disease-modifying osteoarthritis drug, we have discovered MMP13 inhibitors that differ greatly from previous MMP inhibitors; they do not bind to the catalytic zinc ion, they are noncompetitive with respect to substrate binding, and they show extreme selectivity for inhibiting MMP13. By structure-based drug design, we generated an orally active MMP13 inhibitor that effectively reduces cartilage damage in vivo and does not induce joint fibroplasias in a rat model of musculoskeletal syndrome side effects. Thus, highly selective inhibition of MMP13 in patients may overcome the major safety and efficacy challenges that have limited previously tested non-selective MMP inhibitors. MMP13 inhibitors such as the ones described here will help further define the role of this protease in arthritis and other diseases and may soon lead to drugs that safely halt cartilage damage in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.-P., & Fahmi, H. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.196 · Cited by 2,778
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease
Wang, X., & Khalil, R. A. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.08.002 · Cited by 754
Little, C. B., Barai, A., Burkhardt, D., Smith, S. M., Fosang, A. J., Werb, Z., Shah, M., & Thompson, E. W. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25002 · Cited by 642
Proteases involved in cartilage matrix degradation in osteoarthritis
Troeberg, L., & Nagase, H. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.06.020 · Cited by 579
Overview of MMP-13 as a Promising Target for the Treatment of Osteoarthritis
Hu, Q., & Ecker, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041742 · Cited by 475
Osteochondral alterations in osteoarthritis
Suri, S., & Walsh, D. A. (2012) · Bone · doi:10.1016/j.bone.2011.10.010 · Cited by 331
Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?
Murphy, G., & Nagase, H. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0727 · Cited by 316
Jacobsen, J. A., Major Jourden, J. L., Miller, M. T., & Cohen, S. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.08.006 · Cited by 313
Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions
Cho, Y., Jeong, S., Kim, H., Kang, D., Lee, J., Kang, S.-B., & Kim, J.-H. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00710-y · Cited by 296
Pharmacologic therapy for osteoarthritis—the era of disease modification
Hunter, D. J. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.178 · Cited by 288
Post-traumatic osteoarthritis: from mouse models to clinical trials
Little, C. B., & Hunter, D. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.72 · Cited by 286
Matrix metalloproteinase proteomics: substrates, targets, and therapy
Morrison, C. J., Butler, G. S., Rodríguez, D., & Overall, C. M. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.06.006 · Cited by 266
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Matrix metalloproteinase collagenolysis in health and disease
Amar, S., Smith, L., & Fields, G. B. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.04.015 · Cited by 194
New strategies for targeting matrix metalloproteinases.
Fields, G. B. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.01.002 · Cited by 98
Matrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges
Zipfel, P., Rochais, C., Baranger, K., Rivera, S., & Dallemagne, P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00352 · Cited by 94
Metadata
- Authors
- Johnson, A. R., Pavlovsky, A. G., Ortwine, D. F., Prior, F., Man, C.-F., Bornemeier, D. A., Banotai, C. A., Mueller, W. T., McConnell, P., Yan, C., Baragi, V., Lesch, C., Roark, W. H., Wilson, M., Datta, K., Guzman, R., Han, H.-K., & Dyer, R. D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 282
- Issue
- 38
- Pages
- 27781-27791
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2124456960
- Cited by
- 212
- References
- 0
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.